Ferguson Tanner J, Berdahl John P, Schweitzer Justin A, Sudhagoni Ramu
*University of South Dakota Sanford School of Medicine ‡Master of Public Health Program, School of Health Sciences, University of South Dakota †Vance Thompson Vision, Sioux Falls, SD.
J Glaucoma. 2016 Nov;25(11):896-900. doi: 10.1097/IJG.0000000000000529.
The purpose of the study was to evaluate the safety and efficacy of the iStent Trabecular Micro-Bypass stent in pseudophakic patients with open-angle glaucoma.
Retrospective, consecutive case series from October 2012 to May 2015 with no exclusion criteria. The series comprised 42 pseudophakic eyes with open-angle glaucoma that were implanted with 1 iStent. Data were collected preoperatively, and postoperative data were collected at 1 day, 1 week, 1, 3 and 6 months, 1 year, 18 months and 2 years. Data included intraocular pressure (IOP), number of glaucoma medications, the incidence of postoperative IOP pressure spikes ≥15 mm Hg at any timepoint, and the need for additional surgery.
The mean preoperative IOP was 20.26±6.00 mm Hg. At 1 year postoperatively, the mean IOP was 16.34±3.78 mm Hg (P<0.01). At 2 years postoperatively, the mean IOP was 13.62±4.55 (P<0.01). The mean number of glaucoma medications was 1.95±1.01 preoperative and 1.69±1.28 (P>0.05) at 1 year postoperatively. Postoperatively, 3 eyes (7%) experienced an IOP increase of 15 mm Hg above their baseline IOP that responded to topical therapy. In total, 96% of patients with an IOP≥19 mm Hg achieved a reduction in IOP at their last collected follow-up.
The insertion of the iStent Trabecular Micro-Bypass stent effectively lowers IOP in pseudophakic patients with open-angle glaucoma. Although medication use was not significantly reduced postoperatively at 1 year, 80% of patients either experienced a reduction or no change in medication use. The safety profile appears favorable with a low rate of IOP spikes and only 1 patient requiring additional surgery.
本研究旨在评估iStent小梁微旁路支架在人工晶状体植入术后开角型青光眼患者中的安全性和有效性。
回顾性、连续性病例系列研究,时间跨度为2012年10月至2015年5月,无排除标准。该系列包括42只人工晶状体植入术后开角型青光眼眼睛,均植入1枚iStent。术前收集数据,术后在1天、1周、1、3和6个月、1年、18个月及2年收集数据。数据包括眼压(IOP)、青光眼药物使用数量、术后任何时间点眼压升高≥15 mmHg的发生率以及是否需要额外手术。
术前平均眼压为20.26±6.00 mmHg。术后1年,平均眼压为16.34±3.78 mmHg(P<0.01)。术后2年,平均眼压为13.62±4.55(P<0.01)。术前青光眼药物平均使用数量为1.95±1.01,术后1年为1.69±1.28(P>0.05)。术后,3只眼睛(7%)眼压较基线眼压升高15 mmHg,经局部治疗后缓解。总体而言,眼压≥19 mmHg的患者中,96%在最后一次随访时眼压降低。
iStent小梁微旁路支架的植入有效降低了人工晶状体植入术后开角型青光眼患者的眼压。虽然术后1年药物使用量未显著减少,但80%的患者药物使用量减少或未改变。安全性良好,眼压升高发生率低,仅1例患者需要额外手术。